文献速递慢性肾脏病遗传性与小管间质肾病

靶向磷脂酶D4减轻肾脏纤维化

Targeting Phospholipase D4 Attenuates Kidney Fibrosis.
PubMed 文献 · J Am Soc Nephrol · 2017-08-16

在慢性和叶酸性肾纤维化小鼠模型中,磷脂酶D4(PLD4)在近端和远端小管上皮细胞高表达;全局或近端小管条件性敲低PLD4可减轻纤维化。机制涉及调节免疫应答、TGF-β信号、α1-抗胰蛋白酶和中性粒细胞弹性蛋白酶(NE),以及结合TrkA相关蛋白影响MAPK信号。siRNA靶向PLD4治疗可保护小鼠免受叶酸性肾纤维化。

要点

  • PLD4在纤维化肾脏小管上皮细胞高表达,敲低可减轻纤维化。
  • PLD4通过调节TGF-β信号、NE和MAPK通路促进纤维化。
  • siRNA靶向PLD4可治疗叶酸性肾纤维化,提示潜在新策略。

核心结论

  • 抑制PLD4可通过激活蛋白酶介导的细胞外基质降解来减轻肾脏纤维化。

研究设计与样本

  • 研究使用慢性进行性纤维化小鼠模型和叶酸性肾纤维化小鼠模型,结合全局和近端小管条件性基因沉默,以及体外实验和siRNA治疗干预。

主要发现

  • PLD4在纤维化小鼠和人类肾脏的近端和远端小管上皮细胞中过表达。
  • 全局或近端小管条件性敲低PLD4可保护小鼠免于纤维化发展。
  • 全局敲除PLD4调节先天性和适应性免疫应答,并减弱TGF-β信号通路和α1-抗胰蛋白酶蛋白表达上调及中性粒细胞弹性蛋白酶(NE)表达下调。
  • 体外NE处理减弱TGF-β诱导的纤维化标志物积累。
  • siRNA靶向PLD4治疗保护小鼠免受叶酸性肾纤维化,并抑制TGF-β信号增加、NE表达下降和MAPK信号上调。

临床怎么用

  • PLD4抑制可能作为激活蛋白酶介导的细胞外基质降解、逆转纤维化的新型治疗策略。

局限性

  • 研究主要基于小鼠模型和体外实验,人类肾脏样本仅观察到PLD4过表达,尚未在人体中验证治疗靶向PLD4的安全性和有效性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Phospholipase D4 (PLD4), a single-pass transmembrane glycoprotein, is among the most highly upregulated genes in murine kidneys subjected to chronic progressive fibrosis, but the function of PLD4 in this process is unknown. Here, we found PLD4 to be overexpressed in the proximal and distal tubular epithelial cells of murine and human kidneys after fibrosis. Genetic silencing of PLD4, either globally or conditionally in proximal tubular epithelial cells, protected mice from the development of fibrosis. Mechanistically, global knockout of PLD4 modulated innate and adaptive immune responses and attenuated the upregulation of the TGF-β signaling pathway and α1-antitrypsin protein (a serine protease inhibitor) expression and downregulation of neutrophil elastase (NE) expression induced by obstructive injury. In vitro, treatment with NE attenuated TGF-β-induced accumulation of fibrotic markers. Furthermore, therapeutic targeting of PLD4 using specific siRNA protected mice from folic acid-induced kidney fibrosis and inhibited the increase in TGF-β signaling, decrease in NE expression, and upregulation of mitogen-activated protein kinase signaling. Immunoprecipitation/mass spectrometry and coimmunoprecipitation experiments confirmed that PLD4 binds three proteins that interact with neurotrophic receptor tyrosine kinase 1, a receptor also known as TrkA that upregulates mitogen-activated protein kinase. PLD4 inhibition also prevented the folic acid-induced upregulation of this receptor in mouse kidneys. These results suggest inhibition of PLD4 as a novel therapeutic strategy to activate protease-mediated degradation of extracellular matrix and reverse fibrosis.

来源:J Am Soc Nephrol,查看原文。版权归原作者所有。

引用

  1. Trivedi P, Kumar RK, Iyer A, et al. Targeting Phospholipase D4 Attenuates Kidney Fibrosis. J Am Soc Nephrol. 2017. PMID: 28814511. doi:10.1681/ASN.2016111222

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。